Preferred reliever strategy in modern asthma guidelines combining bronchodilation and anti-inflammatory effect
What is: PRN low dose ICS-formoterol
Initial maintenance therapy for symptomatic COPD without frequent exacerbations
What is: A bronchodilator
Device covering LABA/LAMA/ICS combination
What is: Trelegy Ellipta, Enerzair Breezhaler
This short acting bronchodilator is associated with tachycardia, tremors and palpilations
Blood eosinophil threshold warranting ICS therapy
What is: > 300 cells/uL
What is: MDI
This short acting bronchodilator has a slower onset than it's short acting counterpart
What is: SAMA
Important ICS adverse effect risk in COPD
What is: pneumonia risk
This inhaler type might not be compatible with a person with low coordination or dexterity
What is: Handihaler, Breezhaler
Uncontrolled asthma on low dose ICS-formoterol MART, what is the next common pharmacologic escalation?
What is: increase to medium dose of ICS-formoterol for maintenance
First pharmacologic escalation is symptoms persist on single long acting bronchodilator
What is: dual bronchodilator therapy (LABA/LAMA)
This inhaler type has audio/visual dose confirmation
What is: Genuair DPI
During early asthma exacerbation, some action plans recommend temporarily increasing this ICS medication dose up to this amount.
What is: quadrupling ICS dose
High risk COPD exacerbation history per CTS definition
What is: 2+ moderate exacerbations or 1+ severe exacerbation
This inhaler type doesn't require high inspiratory force
What is: Respimat, MDI (with spacer)